---
title: "Nucala (mepolizumab) in severe eosinophilic asthma: Clinical trials questions"
description: "Clinical trials questions on Nucala (mepolizumab) in severe eosinophilic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Pediatric efficacy, and Long-term data. Questions: How much did Nucala reduce severe asthma exacerbations vs placebo (MENSA)? Does Nucala reduce asthma hospitalizations or ER visits vs placebo? Does Nucala reduce oral steroid use in severe asthma (SIRIUS)? Does Nucala improve lung function (FEV1) in severe asthma? 7 further questions follow. 11 questions quoted from 6 sources."
canonical: "https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab) in severe eosinophilic asthma: Clinical trials questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)

Questions that apply to every indication of Nucala are on [Nucala (mepolizumab), all indications](https://www.evicenter.com/medical-information/nucala).

## Study results

<a id="nucala-mensa-exacerbations"></a>

### How much did Nucala reduce severe asthma exacerbations vs placebo (MENSA)?

> “Description of Trial 2: 32-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled study comparing treatment with NUCALA or mepolizumab 75 mg IV to placebo, each added to SOC, in 576 patients ≥12 years of age with severe eosinophilic asthma (SEA).”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Description%20of%20Trial%202%3A%2032%2Dweek%2C,with%20severe%20eosinophilic%20asthma%20%28SEA%29.)

This passage is in a collapsed section of the page; select: Trial 2: Study design, description, primary endpoint, and baseline characteristics

> “Primary endpoint: Exacerbations*/year for NUCALA vs placebo, 0.83 vs 1.74, 53% reduction (P<0.001).”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Primary%20endpoint%3A%20Exacerbations%2A%2Fyear%20for%20NUCALA,vs%201.74%2C%2053%25%20reduction%20%28P%3C0.001%29.)

This passage is in a collapsed section of the page; select: Trial 2: Study design, description, primary endpoint, and baseline characteristics

> “*Defined as worsening of asthma requiring: systemic corticosteroids or hospitalization or ED visit; or at least double the existing maintenance systemic corticosteroid dose for ≥3 days.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=%2ADefined%20as%20worsening%20of%20asthma,corticosteroid%20dose%20for%20%E2%89%A53%20days.)

This passage is in a collapsed section of the page; select: Trial 2: Study design, description, primary endpoint, and baseline characteristics

> “MENSA 
> Placebo (n = 191) 
> 1.74”

Source: [NUCALA: Prescribing information, page 22, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=22)

> “NUCALA 100 mg SC (n = 194) 
> 0.83 
> 0.91 
> 0.47 
> (0.35, 0.64)”

Source: [NUCALA: Prescribing information, page 22, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=22)

Note: The HCP site calls MENSA Trial 2. In the label rows, the values after each group are exacerbations per year, then for NUCALA the rate difference and rate ratio (95% CI) versus placebo.

<a id="nucala-hospitalizations"></a>

### Does Nucala reduce asthma hospitalizations or ER visits vs placebo?

> “61% reduction in exacerbations/year requiring hospitalization/ED visit (0.08 vs 0.20, P=0.02), secondary endpoint.<sup>1</sup>”

Source: [NUCALA: SEA Comorbidity Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/comorbidity-data/#:~:text=61%25%20reduction%20in%20exacerbations%2Fyear%20requiring%20hospitalization%2FED%20visit%20%280.08%20vs%200.20%2C%20P%3D0.02%29%2C%20secondary)

> “Trial 2: 69% reduction in exacerbations requiring hospitalization with NUCALA vs placebo, 0.03 vs 0.10, rate ratio: 0.31 (95% CI: 0.11, 0.91).<sup>1</sup> Results are descriptive.”

Source: [NUCALA: SEA Comorbidity Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/comorbidity-data/#:~:text=Trial%202%3A%2069%25%20reduction%20in,Results%20are%20descriptive.)

> “Exacerbations requiring hospitalization/emergency room visit”

Source: [NUCALA: Prescribing information, page 22, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=22)

> “MENSA 
> Placebo (n = 191) 
> 0.20”

Source: [NUCALA: Prescribing information, page 22, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=22)

> “NUCALA 100 mg SC (n = 194) 
> 0.08 
> 0.12 
> 0.39 
> (0.18, 0.83)”

Source: [NUCALA: Prescribing information, page 22, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=22)

Note: All passages report the 32-week placebo-controlled trial that the HCP site calls Trial 2 (MENSA in the Prescribing Information); the first figure is the secondary endpoint of exacerbations requiring hospitalization or an emergency department visit. Both passages from the HCP site report the full trial population (NUCALA n = 194, placebo n = 191). In the label rows, the values after each group are exacerbations per year, then for NUCALA the rate difference and rate ratio (95% CI) versus placebo.

<a id="nucala-ocs-reduction"></a>

### Does Nucala reduce oral steroid use in severe asthma (SIRIUS)?

> “Description of Trial 3: 24-week, multicenter, randomized, double-blind, placebo-controlled study comparing treatment with NUCALA to placebo in 135 patients ≥12 years of age with severe eosinophilic asthma (SEA) requiring daily OCS in addition to regular use of high-dose ICS* plus an additional controller. Patients were not required to have a history of exacerbations in the previous 12 months.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Description%20of%20Trial%203%3A%2024%2Dweek%2C,in%20the%20previous%2012%20months.)

On the page, select: Trial 3: Study design, description, and primary endpoint

> “Efficacy was assessed using an endpoint of the percent reduction of OCS 
> dose during Weeks 20 to 24 compared with baseline dose, while maintaining asthma control.”

Source: [NUCALA: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=24)

> “Compared with placebo, patients receiving NUCALA 100 mg 
> achieved greater reductions in daily maintenance OCS dose, while maintaining asthma control. 
> Sixteen (23%) patients in the group receiving NUCALA 100 mg versus 7 (11%) in the placebo 
> group had a 90% to 100% reduction in their OCS dose. Twenty-five (36%) patients in the group 
> receiving NUCALA 100 mg versus 37 (56%) in the placebo group were classified as having no 
> improvement for OCS dose. Additionally, 54% of patients receiving NUCALA 100 mg achieved 
> at least a 50% reduction in the daily prednisone dose compared with 33% of patients receiving 
> placebo (95% CI for difference: 4%, 37%).”

Source: [NUCALA: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=24)

> “Trial 3: 14% of NUCALA patients vs 8% of placebo patients completely eliminated daily OCS while maintaining asthma control at Weeks 20-24.<sup>1</sup>
>
> Results are descriptive.”

Source: [NUCALA: SEA OCS Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/ocs-reduction/#:~:text=Trial%203%3A%2014%25%20of%20NUCALA,Results%20are%20descriptive.)

Note: The HCP site calls SIRIUS Trial 3.

<a id="nucala-lung-function"></a>

### Does Nucala improve lung function (FEV1) in severe asthma?

> “Change from baseline in mean forced expiratory volume in 1 second (FEV1) was measured in all 
> 3 trials and is presented in Table 7. Compared with placebo, NUCALA 100 mg did not provide 
> consistent improvements in mean change from baseline in FEV1.”

Source: [NUCALA: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=24)

> “Table 7. Change from Baseline in FEV1 (mL) in Severe Asthma Trials 
> Trial 
> Difference from Placebo in Mean Change from Baseline FEV1 (mL) (95% CI) 
> Week 12 
> Week 24 
> Weeks 32/52 
> DREAM<sup>a</sup> 
> 10 (-87, 108) 
> 5 (-98, 108) 
> 61 (-39, 161)<sup>b</sup> 
> MENSA<sup>c</sup> 
> 52 (-30, 134) 
> 76 (-6, 159) 
> 98 (11, 184)<sup>d</sup> 
> SIRIUS<sup>c</sup> 
> 56 (-91, 203) 
> 114 (-42, 271) 
> NA 
> FEV1 = forced expiratory volume in 1 second, CI = confidence interval. 
> <sup>a</sup> Dose = 75 mg intravenous. 
> <sup>b</sup> FEV1 at Week 52. 
> <sup>c</sup> Dose = 100 mg subcutaneous. 
> <sup>d</sup> FEV1 at Week 32.”

Source: [NUCALA: Prescribing information, page 25, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=25)

Note: In DREAM the dose was mepolizumab 75 mg intravenously (footnote a); the label states that NUCALA is not indicated for intravenous use.

<a id="nucala-asthma-control"></a>

### Does Nucala improve asthma control scores vs placebo (MENSA, ACQ-5)?

> “MENSA was a 32-week placebo- and 
> active-controlled trial in patients with severe asthma with a history of 2 or more exacerbations in 
> the previous year despite regular use of high-dose ICS plus additional controller(s) with or 
> without OCS. Patients received mepolizumab 75 mg intravenously (n = 191), NUCALA 100 mg 
> (n = 194), or placebo (n = 191) once every 4 weeks for 32 weeks.”

Source: [NUCALA: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=21)

> “The Asthma Control Questionnaire-5 (ACQ-5) was assessed in Trials DREAM and MENSA, 
> and the St. George’s Respiratory Questionnaire (SGRQ) was assessed in MENSA.”

Source: [NUCALA: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=23)

> “the ACQ-5 responder rate (defined as a decrease in score of 0.5 or more as 
> threshold)”

Source: [NUCALA: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=23)

> “In MENSA, 
> the ACQ-5 responder rate for the treatment arm for NUCALA 100 mg was 57% compared 
> with 45% for placebo with an OR of 1.8 (95% CI: 1.2, 2.8).”

Source: [NUCALA: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=24)

<a id="nucala-quality-of-life"></a>

### Does Nucala improve quality of life in severe asthma (SGRQ)?

> “MENSA was a 32-week placebo- and 
> active-controlled trial in patients with severe asthma with a history of 2 or more exacerbations in 
> the previous year despite regular use of high-dose ICS plus additional controller(s) with or 
> without OCS. Patients received mepolizumab 75 mg intravenously (n = 191), NUCALA 100 mg 
> (n = 194), or placebo (n = 191) once every 4 weeks for 32 weeks.”

Source: [NUCALA: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=21)

> “In MENSA, the SGRQ responder 
> rate (defined as a decrease in score of 4 or more as threshold) for the treatment arm for 
> NUCALA 100 mg was 71% compared with 55% for placebo with an OR of 2.1 (95% CI: 1.3, 
> 3.2).”

Source: [NUCALA: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=24)

> “Description: 24-week, multicenter, randomized, double-blind, placebo-controlled study comparing treatment with NUCALA to placebo, each added to SOC, in 551 patients ≥12 years of age with SEA.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Description%3A%2024%2Dweek%2C%20multicenter%2C%20randomized%2C%20double%2Dblind%2C,years%20of%20age%20with%20SEA.)

On the page, select: MUSCA: Study design, description, and primary endpoint

> “Primary endpoint/results: Mean change from baseline in SGRQ total score at Week 24: −15.6 for NUCALA vs −7.9 for placebo; treatment difference of −7.7 (P<0.0001). The improvement in both treatment arms was clinically meaningful.<sup>†</sup>”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Primary%20endpoint%2Fresults%3A%20Mean%20change%20from,both%20treatment%20arms%20was%20clinically)

On the page, select: MUSCA: Study design, description, and primary endpoint

> “<sup>†</sup>Defined as a reduction in score of 4 points or more for minimal clinically important difference.<sup>14</sup>”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=as%20a%20reduction%20in%20score,more%20for%20minimal%20clinically%20important)

On the page, select: MUSCA: Study design, description, and primary endpoint

Note: The first two passages are from MENSA; the others describe MUSCA. SGRQ is the St. George's Respiratory Questionnaire.

## Pediatric efficacy

<a id="nucala-pediatric-evidence"></a>

### How was Nucala's effectiveness established in children 6 to 11?

> “Use of NUCALA in pediatric patients aged 6 to 11 years with severe asthma, and with an 
> eosinophilic phenotype, is supported by evidence from adequate and well-controlled trials in 
> adults and adolescents with additional pharmacokinetic, pharmacodynamic, and safety data in 
> children aged 6 to 11 years. A single open-label clinical trial was conducted in 36 children aged 
> 6 to 11 years (mean age: 8.6 years, 31% female) with severe asthma. Enrollment criteria were the 
> same as for adolescents in the 32-week exacerbation trial (MENSA). Based upon the 
> pharmacokinetic data from this trial, a subcutaneous dose of 40 mg every 4 weeks was 
> determined to have similar exposure to adults and adolescents administered a subcutaneous dose 
> of 100 mg [see Clinical Pharmacology (12.3)]. 
> The effectiveness of NUCALA in pediatric patients aged 6 to 11 years is extrapolated from 
> efficacy in adults and adolescents with support from pharmacokinetic analyses showing similar 
> drug exposure levels for 40 mg administered subcutaneously every 4 weeks in children aged 6 to 
> 11 years compared with adults and adolescents [see Clinical Pharmacology (12.3)]. The safety 
> profile and pharmacodynamic response observed in this trial for children aged 6 to 11 years were 
> similar to that seen in adults and adolescents [see Adverse Reactions (6.1), Clinical 
> Pharmacology (12.2)].”

Source: [NUCALA: Prescribing information, page 14, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=14)

## Long-term data

<a id="nucala-long-term-side-effects"></a>

### What are the long-term side effects of Nucala for severe asthma?

> “Long-Term Safety: Nine hundred ninety-eight patients received NUCALA 100 mg in open-label 
> extension studies, during which additional cases of herpes zoster were reported. The overall 
> adverse event profile has been similar to the severe asthma trials described above.”

Source: [NUCALA: Prescribing information, page 9, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=9)

> “Description: 4.5-year, multicenter, open-label, long-term study assessing the safety, immunogenicity, and efficacy of NUCALA in 347 patients ≥12 years of age with severe eosinophilic asthma (SEA) previously treated in Trial 1 at least 12 months prior and who met eligibility criteria. All patients received NUCALA 100 mg SC added to asthma controller therapy.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Description%3A%204.5%2Dyear%2C%20multicenter%2C%20open%2Dlabel%2C%20long%2Dterm,added%20to%20asthma%20controller%20therapy.)

On the page, select: 4.5-year open-label study: Study design, description, and primary/secondary endpoints

> “Primary endpoints: Long-term safety, including AEs, SAEs, and immunogenicity. Most frequent AEs (≥20%) were viral upper respiratory tract infection, 49%; headache, 29%; asthma,* 27%; upper respiratory tract infection, 23%; bronchitis, 21%. Two SAEs occurred in ≥1% of patients: asthma, 10%; and pneumonia, 2%. A total of 8% of patients had a positive anti-drug antibody result, but all were negative for neutralizing antibodies.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Primary%20endpoints%3A%20Long%2Dterm%20safety%2C%20including,were%20negative%20for%20neutralizing%20antibodies.)

On the page, select: 4.5-year open-label study: Study design, description, and primary/secondary endpoints

> “*Asthma reported as an AE means worsening or exacerbation of asthma.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=%2AAsthma%20reported%20as%20an%20AE%20means%20worsening%20or%20exacerbation%20of%20asthma.)

On the page, select: 4.5-year open-label study: Study design, description, and primary/secondary endpoints

Note: The second and third passages describe COLUMBA, the 4.5-year open-label study.

<a id="nucala-long-term-exacerbations"></a>

### What was the exacerbation rate in the 4.5-year Nucala open-label study?

> “4.5-year open-label study (N=347): 61% reduction in mean rate of exacerbations/year* at 4.5 years vs period between Trial 1<sup>†</sup> and open-label study. Secondary endpoint: Annualized exacerbation rate: 0.68 (95% CI: 0.60, 0.78).<sup>1</sup> All results are descriptive.”

Source: [NUCALA: SEA Long-Term Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/long-term-data-safety/#:~:text=4.5%2Dyear%20open%2Dlabel%20study%20%28N%3D347%29%3A%2061%25,All%20results%20are%20descriptive.)

> “*Based on exacerbations reported from the time a patient enrolled until study withdrawal. Median duration 3.8 years.<sup>2</sup>”

Source: [NUCALA: SEA Long-Term Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/long-term-data-safety/#:~:text=%2ABased%20on%20exacerbations%20reported%20from,study%20withdrawal.%20Median%20duration%203.8)

> “<sup>†</sup>Trial 1 was a 52-week dose-ranging exacerbation trial.”

Source: [NUCALA: SEA Long-Term Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/long-term-data-safety/#:~:text=1%20was%20a%2052%2Dweek%20dose%2Dranging%20exacerbation%20trial.)

<a id="nucala-long-term-access-study"></a>

### What did the 6.4-year Nucala open-label access study show for safety?

> “6.4-year open-label study: Study design, description, study objectives, and safety objectives”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=6.4%2Dyear%20open%2Dlabel%20study%3A%20Study%20design%2C%20description%2C%20study%20objectives%2C%20and%20safety%20objectives)

> “Multicenter, open-label, long-term access study of add-on NUCALA every 4 weeks in 514 patients aged ≥6 years with SEA who met eligibility criteria and were enrolled within 6 months following a prior NUCALA study.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Multicenter%2C%20open%2Dlabel%2C%20long%2Dterm%20access%20study,following%20a%20prior%20NUCALA%20study.)

On the page, select: 6.4-year open-label study: Study design, description, study objectives, and safety objectives

> “There were no unexpected safety findings in this long-term access study of patients aged ≥6 years.*”

Source: [NUCALA: SEA Safety Profile, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/safety-profile/#:~:text=There%20were%20no%20unexpected%20safety,of%20patients%20aged%20%E2%89%A56%20years.%2A)

> “Median exposure to NUCALA: 15.5 months (1-77 months)”

Source: [NUCALA: SEA Safety Profile, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/safety-profile/#:~:text=Median%20exposure%20to%20NUCALA%3A%2015.5%20months%20%281%2D77%20months%29)

> “Serious AEs
>
> Reported in >1% of patients: worsening of asthma (3%)
>
>
>
> Non-serious AEs
>
> Reported in ≥10% of patients: worsening of asthma (30%), lower respiratory tract infection (11%), and headache (10%)”

Source: [NUCALA: SEA Safety Profile, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/safety-profile/#:~:text=Serious%20AEs,infection%20%2811%25%29%2C%20and%20headache%20%2810%25%29)

<a id="nucala-cosmos-safety"></a>

### What side effects occurred in the 52-week Nucala COSMOS extension study?

> “Description: 52-week, multicenter, open-label extension study assessing the safety and efficacy of NUCALA in 651 patients ≥12 years of age with SEA who completed Trial 2 or Trial 3. All patients in the 1-year open-label study received NUCALA added to SOC regardless of their previous treatment allocation (NUCALA, mepolizumab 75 mg IV, or placebo).”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Description%3A%2052%2Dweek%2C%20multicenter%2C%20open%2Dlabel%20extension,75%20mg%20IV%2C%20or%20placebo%29.)

On the page, select: COSMOS: Study design, description, and primary endpoint

> “Primary endpoints/results: Long-term safety, including AEs and SAEs. Most frequent AEs (≥10%): nasopharyngitis, 30%; upper respiratory infection, 16%; asthma,<sup>†</sup> 14%; headache, 14%; bronchitis, 12%; sinusitis, 10%. The only SAE that occurred in ≥1% of patients: asthma.<sup>†</sup>”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Primary%20endpoints%2Fresults%3A%20Long%2Dterm%20safety%2C%20including,occurred%20in%20%E2%89%A51%25%20of%20patients%3A)

On the page, select: COSMOS: Study design, description, and primary endpoint

> “<sup>†</sup>Asthma reported as an AE means worsening or exacerbation of asthma.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=reported%20as%20an%20AE%20means%20worsening%20or%20exacerbation%20of%20asthma.,-AE%3Dadverse%20event%3B%20FP%3Dfluticasone)

On the page, select: COSMOS: Study design, description, and primary endpoint

## Related pages
- [Medical information: Nucala (mepolizumab): Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)
- [Indication](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/pharmacology)
- [Real-world evidence](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/access-and-coverage)
